Superior Efficacy of Denosumab Over Zoledronic Acid in Increasing Femoral Neck Bone Mineral Density in Osteoporosis Patients With Type 2 Diabetes Mellitus
Main finding · Femoral neck BMD, % change from baselineResult — go to the resultLS mean difference 4.59 % 95% CI 0.93%–8.25%Authors' conclusion
The results suggest that DEN should be considered as a potentially better option for T2DM patients who have low femoral neck BMD.
Study context
- Population
- Osteoporotic women with T2D aged 50 to 80 years
- Participants
- 75 vs 45
- Exposure
- Denosumab (DEN) vs ZOL
- DENn = 75
- ZOLn = 45reference
- Outcome
- % change from baseline in BMD, bone turnover markers and FRAX fracture risk
- Follow-up
- 1 year
Methodological detailsopen-label, nonrandomized, allocation by patient preference, propensity score-matched analysis
- Open-label
- Nonrandomized
- Allocation by patient preference
- Propensity score-matched analysis
Main finding
Femoral neck BMD, % change from baseline
LS mean difference
4.59 %
95% CI 0.93%–8.25%
P = 0.017
DENvs ZOL
LS mean difference 4.59 % (95% CI 0.93%–8.25%); P = 0.017
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | LS mean difference (%) (95% CI) | P value | |
|---|---|---|---|
| Osteocalcin, % change · 1 yearGreater suppression with DEN | −20.58 (−39.93 to −1.24) | P = 0.041 | |
| Major osteoporotic fracture risk (FRAX), % change · 1 yearGreater reduction with DEN | −11.20 (−20.76 to −1.64) | P = 0.025 | |
| −40−20020Difference, % (linear scale) |
Original publication
Superior Efficacy of Denosumab Over Zoledronic Acid in Increasing Femoral Neck Bone Mineral Density in Osteoporosis Patients With Type 2 Diabetes Mellitus. Endocr Pract. Published 30 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →